Emerging Markets Earnings Roundup: Pfizer, Lilly (Part 2)
This article was originally published in PharmAsia News
Executive Summary
Despite strong growth in emerging markets, Pfizer says multinationals are unlikely to outgrow the market rate due to competition from local companies; while Eli Lilly strives to gain more business outside the U.S.
You may also be interested in...
Lilly Puts Faith In Late-Stage Assets In Hopes Of Profit Growth In 2014
Lilly is making major bets on the oncology and diabetes drugs in its late-stage pipeline in hopes that these assets will fill the hole left by Zyprexa, and soon Cymbalta.
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.